Pan-Hematology Clinical Updates
A Review of the Treatment Landscape 2026
📍 Hilton Garden Inn San Juan Condado, 886 Ashford Ave, San Juan, 00907, Puerto Rico
🗓️ February 12 - 14, 2026
Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Pan-Hematology Clinical Updates Review 2026, to be held at on February 12 - 14, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Pan-Hematology research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Pan-Hematology Clinical Updates Meeting 2026:
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
olivia.wright@md-education.com
Agenda & Faculty
February 12, 2026 | Day 1
Session I:
Moderated by:
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
9:00 AM
JA
Jessica Altman, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
9:15 AM
CD
Courtney Dinardo, MD
MD Anderson Cancer Center, Houston, TX
9:30 AM
Joshua Zeidner, MD
UNC School of Medicine, Chapel Hill, NC
Session II:
Moderated by:
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
10:50 AM
AF
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA
11:05 AM
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX
11:20 AM
CH
Christopher Hourigan, MD
Virginia Tech FBRI Cancer Research Center, Blacksburg, VA
Session III:
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
1:55 PM
SK
Shaji Kumar, MD
Mayo Clinic, Rochester, MN
2:10 PM
KP
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX
2:25 PM
SL
Sagar Lonial, MD
Emory Winship Cancer Institute, Atlanta, GA
Session IV:
Moderated by:
Noopur Raje, MD
Massachusetts General Hospital, Boston, MA
3:45 PM
SS
Surbhi Sidana, MD
Stanford Medicine, CA
4:00 PM
Treatment of Special Populations: Plasma Cell Leukemia, EMD, Renal Failure
SU
Saad Usmani, MD
Memorial Sloan Kettering Cancer Center, New York, NY
4:15 PM
Update on Waldenström’s Macroglobulinemia
AB
Andrew Branagan, MD
Massachusetts General Hospital, Boston, MA
February 13, 2026 | Day 2
Session V:
Moderated by:
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
9:00 AM
Newly Diagnosed DLBCL
GS
Gilles Salles, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
9:15 AM
Trials and Approaches for Mantle Cell Lymphoma
PM
Peter Martin, MD
NYU Langone Medical Center, New York, NY
9:30 AM
Applications of cfDNA in DLBCL Clinical Care and Trials
MR
Mark Roschewski, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Session VI:
Moderated by:
Christopher Flowers, MD
MD Anderson Cancer Center, Houston, TX
10:50 AM
Applications of cfDNA in FL Clinical Care and Trials
DR
David Russler-Germain, MD
Washington University School of Medicine, St. Louis, MO
11:05 AM
Applying LBCL Molecular Classification to Clinical Care and Trials
MS
Margaret Shipp, MD
Dana-Farber Cancer Institute, Boston, MA
11:20 AM
What’s New in CTCL/PTCL
NM
Neha Mehta-Shah, MD
Washington University School of Medicine, St. Louis, MO
Session VII:
Moderated by:
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
1:55 PM
CHIP / CCUS
Uma Borate, MD
The Ohio State University, Comprehensive Cancer Center, Columbus, OH
2:10 PM
Lower-Risk MDS
Mikkael A. Sekeres, MD
University of Miami Miller School of Medicine, Miami, FL
2:25 PM
Higher-Risk MDS
GG
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX
Session VIII:
Moderated by:
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
3:45 PM
Myelofibrosis
Prithviraj Bose, MD
MD Anderson Cancer Center, Houston, TX
4:00 PM
PV and ET
GH
Gabriela Hobbs, MD
Massachusetts General Hospital, Boston, MA
4:15 PM
Mastocytosis and Other MPN
Andrew Kuykendall, MD
Moffitt Cancer Center, Tampa, FL
February 14, 2026 | Day 3
Session IX: ALL
Moderated by:
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
9:00 AM
PH + ALL
HK
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
9:15 AM
Ph - ALL
AL
Aaron Logan, MD
UCSF health, San Francisco, CA
9:30 AM
CAR-T in ALL
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
Session X: CML/CLL
Moderated by:
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
10:50 AM
Frontline Therapy for CML
Daniel DeAngelo, MD
Dana-Farber Cancer Institute, Boston, MA
11:05 AM
Relapse Refractory CML
GI
Ghayas Issa, MD
MD Anderson Cancer Center, Houston, TX
11:20 AM
Relapse Refractory CLL
William Wierda, MD
MD Anderson Cancer Center, Houston, TX
Olivia Wright
Project Manager
How long has Olivia Wright been in the business?
Olivia Wright has been with MD Education since 2025.
About Olivia Wright
As a Project Manager, I support the delivery of educational events and projects at MD Education, working closely with the project management team to ensure smooth coordination and consistently high-quality execution. With a strong background in organisation and communication, I take pride in maintaining a detail-oriented approach to my work. I am committed to delivering to a high standard and value the opportunity to be part of a team dedicated to advancing clinical education.
